Raymond James Financial Services Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-36,987
| Closed | -$84.3K | – | 3581 |
|
|
2024
Q2 | $84.3K | Buy |
36,987
+5,576
| +18% | +$21.3K | ﹤0.01% | 3259 |
|
|
2024
Q1 | $136K | Sell |
31,411
-2,308
| -7% | -$8.04K | ﹤0.01% | 3181 |
|
|
2023
Q4 | $103K | Sell |
33,719
-9,727
| -22% | -$18.3K | ﹤0.01% | 3126 |
|
|
2023
Q3 | $62.6K | Buy |
43,446
+4,647
| +12% | +$8.99K | ﹤0.01% | 3134 |
|
|
2023
Q2 | $96.6K | Sell |
38,799
-1,626
| -4% | -$4.44K | ﹤0.01% | 3066 |
|
|
2023
Q1 | $108K | Sell |
40,425
-3,723
| -8% | -$17.9K | ﹤0.01% | 3039 |
|
|
2022
Q4 | $240K | Sell |
44,148
-7,835
| -15% | -$65.7K | ﹤0.01% | 2740 |
|
|
2022
Q3 | $649K | Buy |
51,983
+120
| +0.2% | +$1.37K | ﹤0.01% | 2090 |
|
|
2022
Q2 | $256K | Sell |
51,863
-1,762
| -3% | -$9.76K | ﹤0.01% | 2704 |
|
|
2022
Q1 | $408K | Buy |
53,625
+3,383
| +7% | +$32.1K | ﹤0.01% | 2501 |
|
|
2021
Q4 | $513K | Buy |
50,242
+8,949
| +22% | +$114K | ﹤0.01% | 2362 |
|
|
2021
Q3 | $554K | Buy |
41,293
+1,073
| +3% | +$17.5K | ﹤0.01% | 2305 |
|
|
2021
Q2 | $882K | Sell |
40,220
-379
| -0.9% | -$8.42K | ﹤0.01% | 2031 |
|
|
2021
Q1 | $977K | Buy |
40,599
+1,086
| +3% | +$25.2K | ﹤0.01% | 1885 |
|
|
2020
Q4 | $711K | Sell |
39,513
-12,107
| -23% | -$181K | ﹤0.01% | 1928 |
|
|
2020
Q3 | $596K | Buy |
51,620
+15,498
| +43% | +$256K | ﹤0.01% | 1866 |
|
|
2020
Q2 | $876K | Buy |
+36,122
| New | +$597K | ﹤0.01% | 1573 |
|
Raymond James Financial Services Advisors's GTHX Position: Q3 2024 in Review
Raymond James Financial Services Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 36,987 shares — an estimated $84.3K sold.
Raymond James Financial Services Advisors first reported a position in GTHX in Q2 2020 and held it in 17 quarters. The position peaked at $977K in Q1 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Raymond James Financial Services Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Raymond James Financial Services Advisors sold 36,987 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $84.3K.
- Raymond James Financial Services Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2020 and held it in 17 quarters.
- Raymond James Financial Services Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $977K in Q1 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.